NasdaqGS:ONCBiotechs
BeOne Medicines (ONC) Is Up 7.4% After Guidance Hike And Priority Review Win In HER2 Cancer
In the past week, BeOne Medicines AG reported first-quarter 2026 results with revenue of US$1,513.44 million and net income of US$227.36 million, raised its full-year 2026 revenue and GAAP operating income guidance, and filed an omnibus shelf registration of up to about US$9.12 billion in various securities.
The company also received FDA Priority Review and Breakthrough Therapy Designation for its TEVIMBRA and ZIIHERA combination in HER2-positive gastroesophageal adenocarcinoma, supported by...